I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| transit amplifying cell | 3 studies | 33% ± 9% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| transit amplifying cell | 3 studies | 33% ± 9% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| liver | 3 studies | 24% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| uterus | 98% | 75.51 | 167 / 170 | 98% | 6.09 | 452 / 459 |
| bladder | 100% | 60.10 | 21 / 21 | 96% | 5.83 | 486 / 504 |
| breast | 99% | 86.50 | 456 / 459 | 95% | 4.03 | 1059 / 1118 |
| intestine | 93% | 106.96 | 896 / 966 | 98% | 7.61 | 514 / 527 |
| esophagus | 90% | 157.22 | 1306 / 1445 | 99% | 7.88 | 182 / 183 |
| lung | 96% | 81.28 | 556 / 578 | 94% | 5.29 | 1081 / 1155 |
| ovary | 87% | 55.46 | 156 / 180 | 100% | 6.20 | 428 / 430 |
| skin | 99% | 273.85 | 1798 / 1809 | 84% | 3.21 | 398 / 472 |
| stomach | 83% | 69.71 | 298 / 359 | 98% | 8.10 | 281 / 286 |
| kidney | 88% | 51.27 | 78 / 89 | 47% | 0.90 | 426 / 901 |
| adrenal gland | 95% | 61.64 | 245 / 258 | 40% | 0.96 | 91 / 230 |
| prostate | 96% | 97.99 | 235 / 245 | 38% | 0.76 | 192 / 502 |
| pancreas | 44% | 15.88 | 144 / 328 | 83% | 2.03 | 148 / 178 |
| thymus | 94% | 56.08 | 615 / 653 | 28% | 0.74 | 167 / 605 |
| brain | 72% | 75.06 | 1892 / 2642 | 49% | 1.46 | 343 / 705 |
| spleen | 100% | 147.05 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 7.06 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 1.99 | 1 / 1 |
| adipose | 98% | 83.71 | 1183 / 1204 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 97% | 5.28 | 28 / 29 |
| blood vessel | 94% | 55.47 | 1250 / 1335 | 0% | 0 | 0 / 0 |
| liver | 29% | 16.09 | 65 / 226 | 49% | 1.24 | 200 / 406 |
| peripheral blood | 56% | 323.17 | 518 / 929 | 0% | 0 | 0 / 0 |
| heart | 51% | 21.87 | 441 / 861 | 0% | 0 | 0 / 0 |
| muscle | 40% | 14.11 | 325 / 803 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 18% | 0.26 | 14 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0006281 | Biological process | DNA repair |
| GO_2000042 | Biological process | negative regulation of double-strand break repair via homologous recombination |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0000785 | Cellular component | chromatin |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0003677 | Molecular function | DNA binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | PARPBP |
| Protein name | PCNA-interacting partner (PARP-1 binding protein) (PARP1-binding protein) PCNA-interacting partner (PARI) (PARP-1 binding protein) (PARP1-binding protein) (PARPBP) |
| Synonyms | C12orf48 PARI |
| Description | FUNCTION: Required to suppress inappropriate homologous recombination, thereby playing a central role DNA repair and in the maintenance of genomic stability. Antagonizes homologous recombination by interfering with the formation of the RAD51-DNA homologous recombination structure. Binds single-strand DNA and poly(A) homopolymers. Positively regulate the poly(ADP-ribosyl)ation activity of PARP1; however such function may be indirect. . |
| Accessions | ENST00000392909.7 ENST00000537257.5 [Q9NWS1-4] J3KQY3 B4DZ31 ENST00000457614.6 ENST00000412715.3 ENST00000327680.7 [Q9NWS1-1] ENST00000392911.6 [Q9NWS1-2] G8JLI2 A0A0C4DG30 H0Y6B3 ENST00000417507.6 Q9NWS1 B4DT40 ENST00000541394.5 ENST00000543784.5 |
